BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  Deals

  Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters

  Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.

  December 13, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Layoffs

  Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner

  The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to focus its resources on its in vivo platform.

  December 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Postmarket research

  Intercept’s Troubled Drug Ocaliva Linked to ‘Serious Liver Injury’: FDA

  Ocaliva recently failed to secure the FDA’s traditional approval for primary biliary cholangitis due to safety concerns.

  December 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data

  Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos will deprioritize the development of inupadenant after it failed to meet the biotech’s clinical bar in a Phase II study of metastatic non-small cell lung cancer.

  December 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug pricing

  Drug Price Watchdog Calls Out Five Pharmas for Unjustified Price Hikes

  The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to support it. Meanwhile, the makers of these drugs have been reporting double-digit sales growth for many of these products.

  December 13, 2024

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  RSV

  FDA Committee Calls For More Research After Moderna’s RSV Vaccine Safety Issues

  Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, FDA advisors said the trial investigators should continue the study, while keeping an eye out for further safety signals.

  December 13, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• Press Releases

  Novellia Data Shown to Optimize Risk Profiling to Inform HER2+ Breast Cancer Care

  December 13, 2024

   · 

  5 min read
• Press Releases

  AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

  December 13, 2024

   · 

  3 min read
• Press Releases

  Landmark Lumbar Total Disc Replacement Study of Nearly 1,200 Patients Supports Long-term Clinical Success and Durability of Centinel Spine’s prodisc® L System

  December 13, 2024

   · 

  5 min read
• Press Releases

  Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint® and BluePrint® for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024

  December 13, 2024

   · 

  7 min read